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Abstract. Centronuclear myopathies are a group of congenital myopathies characterized by severe muscle weakness, genetic
heterogeneity, and defects in the structural organization of muscle fibers. Their names are derived from the central position
of nuclei on biopsies, while they are at the fiber periphery under normal conditions. No specific therapy exists yet for these
debilitating diseases. Mutations in the myotubularin phosphoinositides phosphatase, the GTPase dynamin 2, or amphiphysin 2
have been identified to cause respectively X-linked centronuclear myopathies (also called myotubular myopathy) or autosomal
dominant and recessive forms. Mutations in additional genes, as RYR1, TTN, SPEG or CACNA1S, were linked to phenotypes
that can overlap with centronuclear myopathies. Numerous animal models of centronuclear myopathies have been studied over
the last 15 years, ranging from invertebrate to large mammalian models. Their characterization led to a partial understanding
of the pathomechanisms of these diseases and allowed the recent validation of therapeutic proof-of-concepts. Here, we review
the different therapeutic strategies that have been tested so far for centronuclear myopathies, some of which may be translated
to patients.
Keywords: Centronuclear myopathy, myotubular myopathy, myotubularin, amphiphysin, dynamin, gene therapy, autophagy,
phosphoinositides, oligonucleotide, neuropathy
BACKGROUND
Centronuclear myopathies (CNM) are usually
defined as congenital myopathies with abnormally
positioned nuclei in the center of myofibers, in the
absence of increased muscle regeneration commonly
observed in dystrophies [1]. Of note, CNM are linked
with a general disorganization of myofibers, with
abnormal positioning of different organelles, internal
membrane alterations and often myofibrillar mis-
alignment and fiber shape defects.
Since the first clinical and histopathological
description of a 12-year-old affected boy with myotu-
bular myopathy in 1966 by Spiro et al. [2], remark-
1BSC and JL have equally contributed.
∗Correspondence to: Jocelyn Laporte. Tel.: +33 0 388653412;
E-mail: jocelyn@igbmc.fr.
able advances have been made in understanding
the physiopathology of CNM. A major step for-
ward was the identification of the causative genetic
anomalies. MTM1 was the first identified gene
mutated in the most severe form of CNM: X-linked
centronuclear or myotubular myopathy (XLMTM,
CNMX, OMIM#310400) [3, 4]. This form is char-
acterized clinically by a severe hypotonia and a
generalized muscle weakness often leading to res-
piratory failure and swallowing difficulties, and
usually correlated with a poor prognosis [5–7]. In
the vast majority of cases, loss-of-function muta-
tions cause a strong decrease of the MTM1 protein
[8, 9], a phosphoinositides phosphatase implicated
in multiple cellular processes such as endosomal
trafficking [10–12], excitation-contraction coupling
[13, 14], intermediate filament organization [15],
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neuromuscular junction (NMJ) structure [16, 17],
satellite cell proliferation [18–20], and autophagy
[21, 22]. Female carriers can display a wide spectrum
of clinical and pathological involvement [23].
The autosomal dominant (ADCNM) form is
mainly caused by mutations in the dynamin 2
(DNM2) gene (ADCNM; OMIM#160150) [24]. The
severity ranges from severely affected infant to mildly
affected adults [25]. In severe early onset cases,
infants present with generalized muscle weakness,
hypotonia with facial weakness in addition to oph-
thalmoplegia [26], while in the late-onset milder
cases, young adult patients present with moderate
muscle weakness leading to motor defects [27].
DNM2 is a GTPase mechanoenzyme involved in
endocytosis [28], exocytosis [29, 30], intracellular
membrane trafficking [31–33] and cytoskeletal orga-
nization [34–36]. In vitro studies showed that CNM
mutations in DNM2 increase the GTPase activity and
promote higher stability of polymers, suggesting a
gain-of-function mechanism in ADCNM [37, 38].
This is supported by the appearance of a CNM-like
phenotype in mice over-expressing wildtype DNM2
[39, 40].
Mutations in the BIN1 gene encoding amphiphysin
2 have been reported in CNM patients linked to two
modes of inheritance: autosomal recessive [41, 42]
and autosomal dominant [43] (OMIM#255200). A
large variability in severity is observed in affected
patients, however the main consistent presentation
is muscular atrophy with diffuse muscle weakness
[1, 44, 45]. BIN1 generates and maintains membrane
curvature and tubulation through the BAR domain
[46], while the SH3 domain is involved in recruitment
of endocytotic proteins such as DNM2 [41, 47, 48].
Recessive mutations decrease the membrane tubu-
lation properties of BIN1 [41]. Of note, BIN1 also
binds phosphoinositides and MTM1 [46, 47, 49, 50],
suggesting a common pathway linking MTM1, BIN1
and DNM2 [51].
The incidence of CNM is about 1-2 per 100,000
births, comprised of mutations in MTM1 (∼50%),
DNM2 (∼15%) or BIN1 (∼3%), other implicated
genes (∼12%), or CNM with unknown genetic basis
(∼20%) [52]. Mutations in Ryanodine receptor 1
(RYR1) [53, 54], Titin (TTN) [55], SPEG [56],
DHPR (CACNA1S) [57], ZAK [58], and potentially
myotubularin-related protein 14 (MTMR14) [59] and
CCDC78 [60], have been reported to cause congenital
myopathies with a CNM-like phenotype. We con-
centrate here on CNM linked to MTM1, BIN1 or
DNM2, as these forms present with highly similar
pathogenesis and most translational research has
focused on these forms in the recent years. We provide
a summary of the different preclinical therapeutic
developments that have been explored for XLMTM
and autosomal forms of CNM.
INCREASING OUR UNDERSTANDING
OF CNM THROUGH PHENOTYPING
OF ANIMAL MODELS
Development of different animal models and their
characterization greatly accelerated the understand-
ing of the clinical, physiopathological and molecular
aspects of CNM (Table 1). CNM, or their molecular
defects, have been modelled and studied in cultured
cells, yeast, drosophila, zebrafish, mice and dogs [51].
Moreover, they represent precious tools to test and
validate the different therapeutic approaches preclin-
ically before embarking on clinical trials.
Three different mouse lines were developed to
mimic XLMTM. TheMtm1knockout (KO) mice with
a complete knockdown of the MTM1 protein present
a progressive myopathy starting from around week 3
with a shortened lifespan to around 7-8 weeks of age
[13, 61]. They exhibit similar features to XLMTM
patients, including muscle atrophy and severe weak-
ness, and muscle biopsies feature small rounded
fibers with a high frequency of abnormal localization
of nuclei and disorganized mitochondrial distri-
bution. Ultrastructural analysis revealed dramatic
decrease of normal triads [13], membrane invagina-
tion implicated in excitation coupling machinery, as
well as sarcomere disorganization and enlargement of
neuromuscular junctions [17, 62]. Additional stud-
ies have shown defects in mitochondrial dynamics,
desmin aggregation and alteration in autophagy and
ubiquitin-proteasome pathways [15, 63]. A knock-in
(KI) mouse carrying the R69C mutation was gen-
erated to mimic a mutation identified in XLMTM
patients with a mild phenotype [64]. The R69C muta-
tion results in exon 4 skipping leading to premature
termination of myotubularin translation. However,
some full-length MTM1 protein was still expressed in
this model, resulting in a milder phenotype compared
toMtm1KO mice, with a median lifespan of 66 weeks.
This observation suggests that expression of a small
amount of MTM1 may have significant clinical bene-
fits in XLMTM. A third mouse model, the Mtm1gt/y ,
was generated using a gene trap strategy, and these
mice survive for at least 41 weeks [22]. Mtm1gt/y
mice present a milder phenotype than Mtm1KO mice
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with a similar histopathology including hypotrophic
fibers with a mild increase in mislocalized organelles
and internal nuclei, and autophagy defects. Overall
these mouse models present with CNM phenotypes
mimicking those observed in patients, making these
models very attractive, and are therefore not surpris-
ingly frequently used in preclinical research.
In addition to murine models, a zebrafish model
of XLMTM was generated using morpholinos [14].
Injection of antisense oligonucleotides into embryos
resulted in reduction of myotubularin expression
resulting in a CNM phenotype including myofiber
hypotrophy, centralization of nuclei, as well as mis-
localization of organelles and NMJ defects [14,
16]. Triad defects were also noted in this model.
These defects caused abnormal dorsal curvature with
impairment in spontaneous movements and swim-
ming capacities. More recently, a novel zebrafish
model for XLMTM was created using zinc finger
nucleases to delete 8-bp in exon 5 of the mtm1 gene
causing a frameshift and premature stop codon [65].
In addition to a shortened survival of 7 days, mutants
present a severe muscular phenotype similar to the
morphant model, including reduced motor abilities,
and morphological and muscle structural defects.
Finally, two naturally occurring canine models
were identified for XLMTM: a Labrador Retriever
dog and a Rottweiler dog with progressive myotubu-
lar myopathy harboring the N155K and Q384P
mutations, respectively, in the MTM1 gene [66, 67].
The affected dogs develop a progressive myopathy
and exhibit CNM features such as gait abnormalities
with muscle weakness, and hypotrophic fibers with
an increase in mis-positioned nuclei and organelles.
A third naturally occurring canine model was iden-
tified with a splicing mutation in BIN1 leading to
a strong decrease in protein level and a rapidly
progressive muscle atrophy coupled with exercise
intolerance and a typical CNM histology [42]. This
latter line represents a model for the recessive form
of BIN1-CNM.
Concerning ADCNM due to DNM2 mutations,
a KI mouse model harboring the most frequent
ADCNM mutation R465W was generated [68].
While the homozygous KI mice present a neonatal
lethality due to metabolic defect including hypo-
glycemia, increased liver glycogen content and
hepatomegaly [69], the heterozygous KI mice are
viable and have a normal lifespan, and develop
a progressive myopathy with impairment of mus-
cle contractile properties, atrophy and defects in
mitochondria and reticular networks [68]. Similarly
to Mtm1KO mice, alterations of autophagy were
reported, in addition to defective clathrin-dependent
endocytosis and calcium homeostasis [68–71]. As
an alternative to germline mouse mutagenesis,
adeno-associated virus (AAV) containing mutant
DNM2-R465W were intramuscularly injected into
WT mice and resulted in development of several
CNM features such as fiber hypotrophy, histological
abnormalities and muscle contraction defects, despite
the endogenous expression of DNM2 [39]. In addi-
tion, overexpression of WT DNM2 in mouse, either
with the same AAV transduction strategy or through
transgenesis, also resulted in a CNM phenotype [39,
40]. These results suggest DNM2-CNM is not due
to haploinsufficiency of DNM2, and support other
in vitro observations suggesting that DNM2 muta-
tions leading to CNM may be gain-of-function [37,
38]. Lastly, a more severe DNM2-CNM mutation,
S619L, was modeled in zebrafish, resulting in severe
weakness and motor defects with histopathological
and NMJ abnormalities [72].
Overall, these animal models recapitulate many
CNM features and have contributed to the identi-
fication of several pathomechanims. They all have
strengths and limitations; the small size and high
offspring number of drosophila and zebrafish make
these models well adapted for preclinical work
including drug screening, whereas the murine mod-
els allow in-depth analysis of the pathomechanisms
in mammal. The canine models have similar body
weight to affected children and are thus better
suited for pharmacokinetic/pharmacodynamic mod-
eling and validation of delivery methods. Based on
their various strengths these animal models were used
in several preclinical studies as discussed below.
GENE, RNA AND ENZYME
REPLACEMENT STRATEGIES
MTM1 (Myotubularin) gene therapy
Gene therapy is a promising therapeutic approach
for many monogenic disorders, especially with
loss-of-function mechanism, which relies on the
knowledge of the implicated genes but not on an
in-depth understanding of the pathomechanisms. It
was thus the first approach tested in CNM models
[73]. Moreover, recent progress has greatly increased
the prospects for successful gene transfer [74–76].
Among the different options, AAV vectors have
emerged as effective and potentially safe candidates
for certain indications such as neuromuscular or
392 H. Tasfaout et al. / Therapeutic targets for CNM
neurodegenerative diseases, hematologic disorders
or heart defects [77, 78]. This is reflected by the
increasing number of successful clinical trials that
have driven the approval and marketing of differ-
ent products based on AAV-gene delivery, such as
alipogene tiparvovec (AAV1-LPLS447X) (commer-
cial name: Glybera®) for lipoprotein lipase deficiency
(LPLD)[79, 80]. MTM1 gene replacement was first
tested through intramuscular injection of Mtm1KO
mice with AAV expressing the Mtm1 cDNA under
the control of a CMV promoter, which resulted in
the recovery of muscle mass and force and a nor-
mal histology [73]. Subsequently, AAV-Mtm1 with
a desmin promoter was administered through loco-
regional or systemic injections in both mice and
dogs lacking MTM1 [81–83]. Significant improve-
ments of survival and whole-body rescue were noted
after a single injection, with increase of muscle force
and mass as well as correction of histopathological
hallmarks of CNM. An absence of obvious toxicity
or immune response was noted, except histological
alteration of cardiac tissue specifically in mice [81].
In treated dogs, amelioration of the phenotype was
seen from 4 weeks post injection, and both survival
and health status were greatly improved. This exciting
proof-of-concept demonstrates the efficacy of gene
therapy-based approaches in both small and large ani-
mals and indicates that postnatal gene replacement
can reverse the XLMTM phenotype.
The selection of the best AAV serotype and
promoter that controls the MTM1 expression is essen-
tial for effective and safe gene delivery. Although
XLMTM patients exhibit mainly a muscular phe-
notype, MTM1 is ubiquitously expressed and might
have other key roles in other tissues and organs.
Tissue-tropism of AAV-Mtm1 should respect the
natural tissue-distribution of MTM1 with similar
expression level specific to each organ. The desmin
promoter is highly active in skeletal and cardiac mus-
cles after systemic delivery in mouse, but not in
dog, resulting in massive overexpression of MTM1
in heart (about 700 fold) with an impact on car-
diac histology [81]. The MTM1 promoter may be an
ideal regulator of myotubularin expression in the dif-
ferent tissues. Furthermore, since MTM1 is barely
expressed in XLMTM patient cells [8, 9], it may be
necessary to ensure that delivering an “exogenous”
protein will not trigger an immune response against
the transgene. Also, as AAVs are present within cells
mostly as non-integrated episomes, normal muscle
turnover will likely lead to loss of transgene expres-
sion and reduce the efficacy; however this may be
less the case for CNM than for the tested dystrophies
as there are no signs of increased muscle regenera-
tion in CNM [1]. Whether re-administration of these
viral vectors several years after the initial infusion
may be necessary, without eliciting immunoresponse,
is unclear. A recent study in dog showed longterm
expression of MTM1 four years after a single AAV-
MTM1 isolated limb perfusion despite decrease in
AAV vector copy number, correlating with near-
normal respiratory and motor functions [82]. Finally,
production of an effective dose of AAV vectors for
human administration presents a manufacturing chal-
lenge and requires high titer solutions ranging from
1013 to 1014 vector genome per kg of body weight
for effective gene delivery to at least vital affected
muscles as shown in several ongoing clinical trials
(NCT03199469, NCT03368742, NCT03375164).
Production of these highly concentrated solutions
relies on the use of costly methods that guarantee
high-quality and reliable lots [84]. Importantly, a clin-
ical trial delivering the AAV-MTM1 gene therapy
to XLMTM patient was started by Audentes Ther-
apeutics (www.audentestx.com, NCT03199469) and
exciting positive preliminary results were very
recently reported (www.audentestx.com). Signifi-
cant improvements of neuromuscular and respiratory
functions were detected, and the earliest treated
patient has become ventilator independent 16 weeks
post-injection.
Myotubularin replacement
Enzymotherapy or enzyme replacement is another
approach that was tested to deliver the MTM1 pro-
tein to myofibers [85]. Preclinical research suggests
a small amount of fully functional myotubularin
is enough to significantly prevent or improve the
disease. Indeed several female carriers are asymp-
tomatic, and there is a tendency for a milder disease
in patients with a residual protein level if the muta-
tion is not in the catalytic site [8]. This is supported
by animal models, such as the Mtm1KI R69C mouse
that produces a small amount of myotubularin and
is less affected than the Mtm1KO mouse [64]. For
enzyme replacement, MTM1 was fused with a single
chain fragment derived from a mouse monoclonal
antibody (3E10Fv) [85]. 3E10Fv fusion proteins
penetrate cells through interactions with the equili-
brative nucleoside transporter 2 (ENT2), a plasma
membrane receptor widely distributed in mammalian
tissues with high abundance in skeletal muscle [86].
Interestingly, the phosphatase activity of the fused
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myotubularin-3E10Fv was similar to myotubularin
alone suggesting that this fusion does not inter-
fere with the enzymatic activity [85]. Intramuscular
injection of 3E10Fv-MTM1 into Mtm1KO mice sig-
nificantly improved the muscle function with an
increase in muscle contraction that may be corre-
lated to the increase in correctly positioned triads
and T-tubules observed by electronic microscopy.
However, no obvious improvement was seen in gen-
eral muscle histology. Assessment of the beneficial
effect of 3E10Fv-MTM1 was limited to intramus-
cular injections to date. Due to the generalized
muscle defect in XLMTM disease, systemic deliv-
ery will be required and the efficacy of systemic
delivery of 3E10Fv-MTM1 remains to be elucidated.
In addition, the manufacturing of this active MTM1
protein for human delivery represents a challenge.
The major advantage of this approach is the flexi-
bility in dosing; however the expected short effect
duration will necessitate a repeated re-administration,
which may induce an immunoresponse against the
3E10Fv-MTM1 complex. Similar therapeutic strate-
gies have been successfully employed especially in
multisystemic lysosomal storage disorders including
alglucosidase alfa (Myozyme®) for Pompe dis-
ease, Agalsidase alfa (Replagal®) or Agalsidase beta
(Fabrazyme®) for Fabry disease, and Imiglucerase
(Cerezyme®) for Gaucher disease [87–90]. These
marketed enzymotherapies showed the feasibility of
such approaches and may be used as a roadmap for a
therapeutic development initiated by Valerion Thera-
peutics (www.valerion.com) based on myotubularin
enzyme replacement for myotubular myopathy.
RNA Trans-splicing for DNM2-related myopathy
DNM2-related CNM is a dominant form of CNM
potentially due to gain-of-function mutations, and
may not be a good target for conventional gene
replacement. Reprogramming the Dnm2 RNA to
replace the mutated part with a normal sequence was
tested in the mouse through spliceosome-mediated
RNA trans-splicing [91, 92]. In this specific exam-
ple, the classical 3’ trans-splicing strategy led to toxic
intermediate. However, the alternative usage of 5’
trans-splicing successfully allowed the detection of
trans-splicing events at the mRNA and protein levels,
both in vitro in fibroblasts and in vivo in WT murine
tibialis muscle [91].
RNA trans-splicing was successful for different
diseases including several myopathies in a pre-
clinical setting [92–96]. This promising strategy
appears still in its infancy and additional stud-
ies will have to improve the in vivo efficiency of
the trans-splicing and the phenotypic rescue, while
carefully investigating potential toxicity linked to
the used pre-trans-splicing molecules. Also, these
molecules have to be vectorized to be efficiently
provided [97].
Allele-speciﬁc RNA silencing for DNM2-related
myopathy
Another approach aiming to decrease the amount
of the mutated DNM2 transcript consisted in silenc-
ing specifically the mutated RNA through the siRNA
technology [98]. Allele-specific siRNA sequences
were developed in order to specifically knock down
the human or murine DNM2-mRNA harboring the
p.R465W mutation without affecting the wild-type
allele. Scanning the sequence encompassing the
mutated site was necessary to identify the best siRNA
molecules efficient in heterozygous Dnm2KI R465W
mouse embryonic fibroblasts. The in vivo proof-
of-concept was obtained in the Dnm2KI R465W
mouse after intramuscular injection of AAV express-
ing the selected shRNA molecules. After 3 months,
most CNM histological signs were partially or
fully rescued, including muscle mass and specific
force, fiber size and central accumulation of oxida-
tive staining. A similar approach was validated
in patient fibroblasts expressing the R465W muta-
tion. The R465W RNA was strongly reduced while
the WT transcript appeared unaffected. This was
correlated with a normalization of endocytosis mea-
sured by transferrin uptake, while this is decreased
in scramble-transfected cells. Overall, this allele-
specific targeting approach appears very specific and
bears promise for future pre-clinical development.
NORMALIZING THE DISEASE PATHWAY
MTMR2 expression
The MTM1 gene has many close homologs,
which may provide an alternative therapeutic option.
Indeed, 14 myotubularins have been identified in
human [99, 100]. They express common protein
domains including the PH-GRAM and coiled-coil
that are implicated in phosphoinositide binding and
in their oligomerization, respectively [4]. Of note,
6 myotubularins do not have an enzymatic activity
and are named dead-phosphatases, while 8 dis-
play a phosphatase activity [4]. The myotubularin
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dead-phosphatases do however regulate their catalyt-
ically active homologs, either by modifying their
subcellular localization or by potentially changing
the allosteric activity [101]. MTM1 and MTMR2
share 65% of amino acid sequence identity and sim-
ilar phosphatase activity [100, 102]. Of note, while
MTM1 is mutated in XLMTM,MTMR2mutations are
linked to demyelinating Charcot-Marie-Tooth neu-
ropathy (CMT4B1; OMIM 601382) [103]. Raess et
al. studied the molecular basis for the functional dif-
ference between MTM1 and MTMR2 [104]. Two
MTMR2 isoforms were previously identified [105].
The most studied and longest isoform has an addi-
tional N-terminal extension prior to the PH-GRAM
domain, which is absent in the short MTMR2 iso-
form. Importantly, unlike the long isoform, the short
MTMR2 isoform displays an MTM1-like activity in
a yeast complementation system and was found to
be downregulated in Mtm1KO muscle [104]. Upon
intramuscular injection of AAV expressing the long
MTMR2 isoform in the Mtm1KO mouse, a signifi-
cant rescue of muscle phenotype was seen, however
a better amelioration in muscle mass, force and his-
tology were observed with the short isoform [104].
In addition, the elevated level of the MTM1 substrate
phosphoinositol-3-phosphate (PtdIns3P) inMtm1KO
muscles was corrected upon this treatment. These
observations suggest that the additional N-terminal
extension in MTMR2 is responsible for the func-
tional difference between MTM1 and MTMR2. More
recently, intravenous administration of a single dose
of the AAV9-Mtmr2 vector in the Mtm1KO mice
was shown to improve the motor activity and mus-
cle strength and prolonged survival throughout a
3-month study [106].
Thus, exogenous overexpression of short MTMR2
isoform or alternative splicing modulation of endoge-
nous MTMR2 transcripts may be potential strategies
to compensate for the loss of MTM1. This strategy
could be applied as an approach to normalize the
phosphoinositides level and treat XLMTM. While the
targeting of an MTM1 homolog may avoid potential
immune response compared to exogenous expression
of the missing MTM1 protein, the rescue may be
less efficient than using MTM1 itself, and the chal-
lenges for the delivery (e.g. AAV) remain as discussed
above.
Rebalancing 3-phosphoinositides level
MTM1 is a PI 3-phosphatase that dephosphory-
lates PtdIns3P and PtdInsp(3,5)P2 into PtdIns and
PtdIns5P respectively [107–109]. Different XLMTM
animal models have shown an increase in PtdIns3P
as a direct consequence of loss of MTM1 [14,
64, 65, 110]. These low-abundant phospholipids
are key regulators of different cellular processes
like membrane trafficking and intracellular signal-
ing [111, 112]. Concerning PtdIns3P, several kinases
were implicated in its generation including class
II (PIK3C2) and class III (PIK3C3 or VPS34) PI
3-kinases. Reducing the elevated PtdIns3P level
was investigated through downregulation or inhi-
bition of these kinases. Based on the observation
made in Drosophila melanogaster showing deple-
tion of the class II PI 3-kinase Pi3K68D rescued the
defects caused by mtm (ortholog of both MTM1 and
MTMR2) deficiency [113], depletion of the class II
PIK3C2B was achieved in Mtm1KO mice through the
production of a double knockout Mtm1KO/muscle-
specific Pikc2BKO [65]. PIK3C2B was potentially
the best candidate to target as its total loss in
mice is viable whereas loss of other PI 3-kinases
including PIK3C3 leads to strong defects [114].
Genetic reduction of PIK3C2B before or after dis-
ease onset prevented or reverted the myopathy and
extended the life expectancy, improved body weight
and restored muscle force and histology. Surpris-
ingly, genetic reduction of PIK3C3 in Mtm1KO mice
(Mtm1KO/Pik3c3 heterozygous) worsened the CNM
phenotype, suggesting that MTM1 and PIKC2B may
control the same sub-pool of PtdIns3P and that block-
ing the phosphorylation activity of PIK3C2B, but
not PIK3C3, would be a therapeutic strategy for
XLMTM. To develop this approach further, the iden-
tification of drugs that can specifically target PIKC2B
is required. In the mtm1 zebrafish model, inhibitors
of PI 3-kinase class I or III, GDC-0941 or VPS34-
IN1 respectively, did not improve the motor function
and morphological defects. In the absence of specific
class II inhibitors, pan PI 3-kinase inhibitors were
tested, including PI-103, LYS294002 and wortman-
nin, and significant improvements of the survival,
motor function and morphology were observed in
the treated larvae [65]. In addition, treatment of
Mtm1KO mice with wortmannin prolonged the sur-
vival, ameliorated the CNM phenotype and histology,
and greatly improved Ca2+ release defects [65, 115].
A great advantage of this therapeutic strategy is
that the target is an enzymatic activity and thus
druggable. The therapeutic window, i.e. the range
of doses which optimize between efficacy and tox-
icity, has to be defined and genetic studies suggested
full depletion of PIK3C2B achieved a better rescue
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than partial depletion [65]. This successful strat-
egy focused on targeting one function of MTM1,
PtdIns3P dephosphorylation, but not PtdIns5P pro-
duction or phosphoinositides-independent functions,
suggesting increased in PtdIns3P is a main cause
of XLMTM. Interestingly, a significant prevention
of CNM phenotypes was also achieved by AAV-
mediated expression of several phosphatase-dead
MTM1 mutants in the Mtm1KO mouse [116] and
confirmed in an independent study [63]. Thus tar-
geting phosphoinositide-independent functions of
MTM1 also appears promising as normalization of
PtdIns3P level was not needed for the rescue of
the intracellular organization of myofibers, including
positioning of nuclei, mitochondria and triads, nor for
muscle force, but seems important for triad shape and
fiber size [116].
In conclusion, inhibiting specifically PIK3C2B in
muscle represents a promising therapeutic approach
in XLMTM; however development of specific
PIK3C2B inhibitors is required, as alteration or inhi-
bition of other PI 3-kinases is highly detrimental
[117].
Normalizing or reducing DNM2 in several forms
of CNM
As mutations in either MTM1 or DNM2 lead to
CNM, it is probable that these proteins act in the
same pathway for normal muscle maturation and/or
maintenance [51]. In vitro experiments showed sev-
eral CNM mutations increase the oligomerization and
GTPase activity of DNM2 [37, 38], and in vivo over-
expression of wildtype DNM2 in mice either through
transgenesis or AAV injection produced a CNM-like
phenotype [39, 40]. Moreover, it was realized that
DNM2 protein level is increased in XLMTM patient
muscles and in muscles from the Mtm1KO mouse
[118]. Based on these results, and the rationale that
DNM2 mutations in CNM are gain-of-function, the
potential therapeutic effect of DNM2 downregulation
was tested in Mtm1KO mice.
To test a negative epistasis between MTM1 and
DNM2, a genetic reduction of DNM2 in Mtm1KO
mice was first investigated in Mtm1KO/Dnm2 het-
erozygous KO animals. Unlike Mtm1KO mice, the
double transgenic mice showed normal lifespan and
whole-body weight, and greatly improved muscle
histology, mass and force [118]. These results were
confirmed recently using antisense oligonucleotides
(ASO) targeting specifically Dnm2 transcript [119].
Systemic ASO delivery in pre-symptomaticMtm1KO
mice efficiently decreased DNM2 expression at RNA
and protein levels and prevented the development
of CNM. More importantly, post-symptomatic ASO
systemic treatment stopped disease progression after
a single injection and reverted CNM phenotypes
within only 2 weeks. In this later experiment, the dis-
ease correction correlated with a normalized DNM2
expression, suggesting that decreasing DNM2 level
to normal range is enough to restore muscle func-
tion in severely affected mice thereby reducing side
effects related to DNM2 reduction below normal
level.
These observations make the reduction/normali-
zation of DNM2 by ASO injection an attractive thera-
peutic approach. Indeed, injection and dosing regime
can be easily adapted during the treatment. In addi-
tion, many clinical trials using ASO have been made
with some ASO-based drugs approved for use in
clinic, such as fomivirsen upon local administration
in Cytomegalovirus retinitis, or systemic delivery of
mipomersen for familial hypercholesterolemia, and
more recently nusinersen and eteplirsen for spinal
muscular atrophy and Duchenne muscular dystrophy,
respectively [120]. Nevertheless, repeated injections
are needed and certain ASO chemistries have been
reported to preferentially distribute into liver and
kidney potentially causing toxicity [121–124]. Thus,
translation of this approach into XLMTM patients
will require the development of efficient and safe
human ASO candidates that allow a preferential tar-
geting of skeletal muscle. Also, DNM2 has important
roles in cellular organization in different tissues;
therefore determining the benefit:risk ratio and to
which extent DNM2 can and needs to be downregu-
lated is a main point being investigated by Dynacure
(www.dynacure.fr) which is developing clinical can-
didates for DNM2 targeting.
The concept of “cross therapy” in CNM, i.e. target-
ing one CNM gene (DNM2) to rescue the myopathy
due to mutations in another CNM gene (MTM1
as above), has been recently further developed by
showing that DNM2 downregulation can also res-
cue BIN1-related CNM [125]. While Bin1KO mice
die at birth from a skeletal muscle defect, Bin1KO
mice with reduced level of DNM2 (Bin1KO/Dnm2
heterozygous KO) survive at least 18 months, and
have normal muscle force and intracellular organiza-
tion of muscle fibers. Modulating DNM2 level thus
represents a first therapeutic concept for patients with
BIN1 defects.
Taken together, these results validate the epistasis
between MTM1, BIN1 and DNM2. Of note, DNM2
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targeting appears to be the first therapeutic strategy
targeting several forms of CNM, suggesting a single
ASO therapy may thus be sufficient to target a wide
range of CNM mutations.
TREATING THE GENERAL MUSCLE
IMBALANCE
XLMTM is characterized by severe muscle atro-
phy with small muscle fibers in Human and animal
models [1, 14, 61, 66]. Moreover, a correlation
between myofiber size, MTM1 mutation and clinical
outcome has been documented by comparing histol-
ogy of XLMTM infant muscle biopsies and prognosis
[126]. Other data on murine and canine models
suggest that a very useful histological indicator of
disease improvement is normalization of myofiber
size together with organelle distribution. These obser-
vations support that therapeutic strategies increasing
fiber size and/or muscle bulk together with myofibers
intracellular organization may be beneficial. The reg-
ulation of muscle mass and fiber size is reflected
by the balance between protein synthesis and degra-
dation, which are controlled by several intracellular
signaling pathways. Major pathways implicated to
date are the IGF1-AKT-mTOR pathway leading to
muscle hypertrophy mainly through increased protein
synthesis, the myostatin-Smad2/3 pathway which is
a negative regulator of protein synthesis, and the
protein degradation pathways, autophagy and the
ubiquitin-proteasome system [127]. These pathways
represent interesting targets that were investigated
mainly for XLMTM.
Targeting cellular homeostasis: Autophagy and
ubiquitin-proteasome system
The ubiquitin-proteasome and autophagy-lyso-
somal pathways play a vital role in cellular homeosta-
sis by degrading damaged organelles and unnecessary
or dysfunctional components such as proteins, and
were shown essential for normal muscle growth
and maintenance [128]. Alterations of these cellular
processes have been reported in different Mtm1-
deficient animals [15, 21, 22, 63]. Analysis of
muscles from Mtm1KO mice revealed an accu-
mulation of ubiquitinated proteins and defective
mitochondria as well as a low conversion rate of
LC3I to LC3II suggesting a blockade of the late
stage of autophagy [15, 22]. In addition, misfolding
and aggregation of intermediate filaments, such as
desmin, were also noted [15]. Loss of MTM1 was
associated with hyperactivation of the IGF1R/AKT/
mTOR pathway reflected by an hyperphosphoryla-
tion of S6K1Thr389, S6ser240/244 and 4EBP1Thr37/46
and an increase of the autophagy induction
marker phospho-ULK1Ser757 [19, 22]. On the other
hand, hypophosphorylation of FoxO3aser318/321, the
transcription factor implicated in muscle protein
degradation, was noted in MTM1-deficient mus-
cles resulting in increased transcription of atrogenes
such as Atrogin1, Murf1, Nedd4 and ZNF2016 [21].
Moreover, a molecular interaction was character-
ized between MTM1 and UBQLN2, an ubiquilin
protein regulating the degradation of ubiquiti-
nated proteins by the proteasome [63]. Taken
together, these results indicate that MTM1-deficiency
results in defects in cellular clearance pathways
and suggest that activating these degradation pro-
cesses may normalize homeostasis of the muscle
fibers.
Pharmacological inhibition of mTOR, a major neg-
ative regulator of autophagy, using the allosteric
inhibitor RAD001 or the ATP-competitive inhibitor
AZD8055 remarkably normalized autophagy mark-
ers by lowering p62 and increasing LC3I/LC3II
conversion [22]. Moreover, AZD8055 treatment in
MTM1-deficient mice had positive effect on mus-
cle mass and reduced the abnormal accumulation
of desmin intermediate filament. These encourag-
ing results highlight the implication of MTM1 in
autophagy-lysosome and ubiquitin-proteasome path-
ways and propose autophagy normalization as a
therapeutic target for XLMTM. As drugs affecting
these pathways are in clinical development for dif-
ferent diseases [129], it may benefit the field of
centronuclear myopathies.
It is worth noting that DNM2 was also reported to
be implicated in autophagy [68, 69]. Liver, skeletal
muscle and fibroblasts of Dnm2 R465W KI mice pre-
sented a defect in autophagosome maturation due to
a decrease in the autophagic flux [69]. As these data
were mainly obtained on cells and mice homozygous
for this specific DNM2 mutation, while DNM2-CNM
is linked to different heterozygous mutations, the
importance of autophagy in the DNM2-CNM forms
remains to be confirmed. To this end it was shown that
fasting in heterozygous animals induced an increase
in LC3-II, p62 and autophagosomes in muscle [69].
These findings suggest a common molecular defect
between XLMTM and ADCNM, and broaden the
therapeutic interest of the autophagy normalization
approach.
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Targeting muscle growth pathways with Activin
Receptor type IIB inhibition
Myostatin, a member of the TGF (transforming
growth factor beta) family, is a highly conserved
negative regulator of skeletal muscle bulk [130].
Furthermore, natural deficiency or pharmacologi-
cal inhibition of the myostatin pathway has been
reported to stimulate muscle growth by increasing
myofiber size and muscle mass [131–135], which
makes anti-myostatin based approaches very attrac-
tive to different muscle wasting conditions including
Duchenne muscular dystrophy [136], amyotrophic
lateral sclerosis [137], sarcopenia [138] and can-
cer cachexia [139, 140]. Indeed, various myostatin
inhibitor approaches have been identified and tested
in preclinical or clinical trials with varying effica-
cies, e.g. gene delivery of follistatin and homologues
[135], myostatin propeptide [141, 142], myostatin
antibodies [136] and more recently a soluble form
of myostatin receptors [143, 144]. In Mtm1KO mice,
administration of a soluble form of the extracellular
region of the myostatin receptor (ActRIIB) fused to
the Fc portion of human IgG resulted in a transient
increase in muscle mass and force and myofiber size,
that was reflected clinically by a significant albeit
modest extension of lifespan [145], whereas no clin-
ical improvements were noted following ActRIIB
injection in the less severely affected Mtm1KI R69C
mice apart from hypertrophy of gastrocnemius mus-
cle [19]. Histology analysis of skeletal muscles of
both treated Mtm1KO or Mtm1KI R69C mice showed
that the hypertrophy was restricted to myofiber
type 2b, suggesting that inhibiting myostatin has an
effect mainly on fibers with low oxidative capaci-
ties. However, in XLMTM cases, muscle biopsies
are characterized by predominance of highly oxida-
tive type 1 fibers [1], which may compromise the
efficacy of this strategy in XLMTM patients. An
explanation for the modest benefit of downregulat-
ing the myostatin pathway in the XLMTM mice
models is that, in the Mtm1KO at least, there is
a strong decrease of myostatin and a correspond-
ing increase of the myostatin antagonist follistatin,
supporting that the myostatin pathway is already
turn down in the disease and thus is not available
for further inhibition [146]. Moreover, despite the
substantial increase in myofiber type 2b size, no
improvement of the excitation-contraction coupling
related defects was noted, supporting myostatin inhi-
bition as a potential additive strategy for increasing
muscle bulk in combination with another strategy
improving excitation-contraction coupling. In addi-
tion to its skeletal muscle expression, myostatin is
also expressed at much lower level in the heart and
adipose tissue. Myostatin null mice exhibit cardiac
hypertrophy with changes in structure and contrac-
tile parameters [147]. Consequently, the benefit:risk
balance for an anti-myostatin approach in XLMTM
should be considered before application on patients.
OTHER POTENTIAL THERAPEUTIC
APPROACHES
Acetylcholinesterase inhibition
Defects of NMJ have been documented in
XLMTM patients and animal models of myotubu-
lar myopathy [16, 17, 148]. This chemical synapse
is where a motoneuron activates muscle contraction
upon the arrival of an action potential at the presynap-
tic neuron leading to a release of neurotransmitters.
Its function is defective in congenital myasthenic
syndromes (CMS) that share some clinical features
with CNM. Previous studies described structural and
functional defects of NMJ in some patients with
CNM without genetic diagnosis at that time [149,
150]. Using electron microscopy, muscle biopsies
from CNM affected neonates showed shallow pri-
mary synaptic clefts with few large synaptic vesicles
indicating a poor NMJ transmission. Furthermore,
similar defects have been observed in a zebrafish
model of XLMTM (mtm1 hypomorphic morpholino
model) or ADCNM transiently overexpressing the
most severe DNM2 S619L mutation [16, 151]. In
fact, these zebrafish models exhibit an abnormal
distribution of acetylcholine receptors that was asso-
ciated with a decrease in swimming capacities, while
treatment with edrophonium, an acetylcholinesterase
inhibitor, dramatically enhanced both spontaneous
and touch evoked movement. Finally, additional stud-
ies confirmed the NMJ defect in two mouse models
of XLMTM, Mtm1KO and Mtm1KI R69C [17, 148].
In Mtm1KO, through either intravital imaging or
examination of muscle sections, NMJs appear larger
and ultrastructural examination revealed simplifica-
tion of post-junctional folds with presence of many
vacuolar structures, resembling NMJ ultrastructure
described in XLMTM patients. In all, these find-
ings suggest a contribution of NMJ defects in the
muscle weakness of CNM patients and a role of
two CNM-causing genes (MTM1 and DNM2) in the
regulation of NMJ. Whether NMJ defects are a pri-
mary defect of the nerve or secondary to muscle
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Fig. 1. Conceptual figure depicting the different cellular defects reported in X-linked and/or autosomal CNM (in red) and indicating the
various therapeutic strategies tested (in green). CNM fibers can be rounder and smaller, especially for the X-linked form. NMJ: neuromuscular
junction.
alteration is not yet known. Importantly, a signifi-
cant clinical improvement was noted in a confirmed
case with XLMTM following treatment with pyri-
dostigmine, an acetylcholinesterase inhibitor which
increases acetylcholine half-life within the synapse
and is commonly used to treat myasthenia gravis and
CMS [16]. Thus, acetylcholinesterase inhibitors may
represent an effective therapy to treat symptoms for
patients with CNM.
Cell transplantation or cell therapy
Cell transplantation has been tested in the clinic
for many diseases with variable positive outcomes
[152]. At present, the most successful trials have
been achieved in hematological diseases using bone
marrow cells which are relatively easy to harvest,
manipulate and replace, and have good safety pro-
files and obvious selective advantages [153, 154].
In contrast, due to the wide tissue distribution and
slow cellular turnover of muscle fibers, stem cell
transplantation showed very limited beneficial effects
when used in muscle disorders [155]. In this field,
the majority of trials focused on Duchenne muscular
dystrophy which is characterized by myofiber degen-
eration/regeneration and satellite cell pool exhaustion
[156–159]. Albeit XLMTM is not a dystrophy, the
number of satellite cells in three different muscles of
XLMTM patients is significantly lower than controls
[20]. The Mtm1KO mice also present a decrease in
satellite cells [18, 19]. In addition, Mtm1KO mus-
cle cells displayed decreased proliferation, increased
apoptosis and poor cell engraftment indicating an
inability of satellite cells to “rebuild” damaged skele-
tal muscle [18] and suggesting cell replacement as a
potential therapeutic option. In the Mtm1KI R69C
mice, a model of mild XLMTM, injection of syn-
geneic skeletal muscle-derived WT myoblasts into
the gastrocnemius resulted in moderate improve-
ments in skeletal muscle mass and force [160]. This
encouraging, albeit limited, positive effect demon-
strated the potency of this approach in XLMTM
disease.
Furthermore, tremendous progress has been
achieved in the isolation of muscle satellite cells
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Table 2
Pros and Cons of the potential therapeutic approaches for centronuclear myopathies
Approach Products Pros Cons
Gene, RNA and protein replacement
MTM1 gene delivery AAV-MTM1; AAV-MTM1 dead
phosphatase
Single injection; longterm
expression; partial
organ-specific delivery
Not fine-tunable; no treatment
interruption; immunity to AAV;
immunity to MTM1
Myotubularin delivery 3E10Fv-myotubularin Fine-tunable; possible
treatment interruption
Re-administration needed;
immunity to MTM1 or 3E10Fv
DNM2 RNA trans-splicing AAV-5’ pre-trans-splicing
nucleotides
Single injection; longterm
expression
Requires DNA delivery (naked,
liposome, viral-based);
potential toxicity of
pre-trans-splicing molecules
Allele-specific DNM2 RNA silencing AAV-shRNA Single injection;
allele-specificity decreasing
on-target toxicity
Late treatment appeared less
efficient for reversion;
immunity to AAV
Normalizing the disease pathway
MTMR2 expression AAV-MTMR2 Single injection; longterm
expression; partial
organ-specific delivery
Not fine-tunable; no treatment
interruption; immunity to AAV
PI3K inhibition Wortmannin; LY294002;
PI-103
Fine-tunable; possible
treatment interruption
Re-administration needed; poor
organ specificity; on-target
toxicity (lack of specific
PIK3C2B inhibitor)
DNM2 reduction or normalization antisense oligonucleotides Fine-tunable; possible
treatment interruption;
sequence substitution
Re-administration needed; poor
organ specificity; on-target
toxicity
AAV-shRNA Single injection; longterm
expression
Not fine-tunable; no treatment
interruption; immunity to AAV;
on-target toxicity
Treating the general muscle unbalance
Autophagy activation mTOR inhibitors (RAD001,
AZD8055)
Fine-tunable; possible
treatment interruption
Re-administration needed; poor
organ specificity; on-target
toxicity
Myostatin inhibition ActRIIB-mFC Fine-tunable; possible
treatment interruption; in
clinical use
Re-administration needed; poor
organ specificity; on-target
toxicity; good histological but
poor functional improvements
in XLMTM model
Other potential approaches
Acetylcholinesterase inhibition pyridostigmine; edrophonium Fine-tunable; possible
treatment interruption; in
clinical use for myopathies
(FDA approved)
Symptomatic treatment
Cell transplantation syngeneic WT myoblasts Ex vivo cell manipulation
possible
Re-administration needed;
systemic delivery difficult;
longterm effect unknown
Notes: Extent of positive outcomes in animal models do not necessarily translate in human. Pros and Cons and mode of delivery may change
depending on results in pre-clinical development and methodological updates.
and understanding the molecular and cellular mech-
anisms that control their activity [156, 161–164].
Combination of autologous cell therapy with other
approaches like ex vivo genome editing or ex
vivo gene replacement may present a safe and
efficient way to achieve a successful cell therapy-
based approach, while avoiding immunoreaction to
exogenous cells in case of allotransplantation. Inter-
estingly, the myostatin inhibition-based approach
described above showed a significant increase of
satellite cells activation in XLMTM animals [19].
Importantly, myostatin inhibition increased the effi-
cacy of myoblast transplantation in other myopathy
models [165], indicating that inhibition of myostatin
could potentiate myoblast transfer. Nonetheless, sys-
temic delivery of stem cells to repopulate most
affected muscles represents the major limitation of
this approach due to the wide distribution required
to target this tissue. Overall, this approach has a
promising future and encouraging perspectives in
400 H. Tasfaout et al. / Therapeutic targets for CNM
XLMTM disease assuming methodological bottle-
necks are solved.
CONCLUSIONS
Substantial advances have been achieved in the
recent years in our understanding of the molecular
pathomechanisms causing CNM, and have allowed
the emergence of therapeutic strategies targeting dif-
ferent cellular defects (Fig. 1) and the creation of
several companies dedicated to developing these
approaches to clinic.
However, while the overlap observed in clini-
cal features, histology and several cellular defects
between different CNM forms suggests a common
pathway where the different mutated proteins may
be involved, the functional interplay between these
proteins and their links with the different cellular
abnormalities are not well understood. Moreover,
a significant number of individuals with CNM-like
phenotype remains without genetic diagnosis, sug-
gesting the implication of other genes. Identification
of novel CNM genes and pathomechanisms will cer-
tainly contribute to the characterization of additional
defective cellular pathways that represent new thera-
peutic targets.
Each of the therapeutic approaches has its own
pros and cons (summarized in Table 2). Current
bottlenecks for translation of therapeutic concepts
achieved in cellular and animal models need to be
overcome, such as increasing efficacy, decreasing
on-target toxicity and off-target effects, benefit sus-
tainability, tissue specific targeting, and vector/drug
production and delivery. A first clinical trial has been
started in 2017 for MTM1 gene therapy, underlin-
ing that myotubular and centronuclear myopathies
are now under attack. The plethora of therapeu-
tic targets recently identified should pave the way
to future combinatorial therapies for the benefit of
patients.
LIST OF ABBREVIATIONS
XLMTM: X-linked myotubular or centronuclear
myopathy
CNM: centronuclear myopathy
ADCNM: autosomal dominant centronuclear
myopathy
MTM1: myotubularin
BIN1: amphiphysin 2
DNM2: dynamin 2
NMJ: neuromuscular junction
PtdIns3P: phosphoinositide 3-monophosphate
PH-GRAM: pleckstrin homology-
glucosyltransferases, Rab-like GTPase
activators and myotubularins
ASO: antisense oligonucleotide
CMS: congenital myasthenic syndrome
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